stockrowOculis Holding AG
Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024.
- Revenue
- −97.2%
- EPS
- +9.20%
- Free cash flow
- −20.9%
- Total debt
- −4.44%
Quarter to September 2026, against a year earlier
Follow OCS
Alert me
Oculis Holding AG (OCS) EV/Sales
As of 6 November 2026, Oculis Holding AG (OCS) trades at a EV/Sales of 176×. Over the past ten years it has ranged from 0.0× (March 2024) to 1,176× (May 2026); the current reading is higher than 53% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 545× | (26.28%) |
| FY2024 | 739× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 273× | (28.72%) |
| Jun 2026 | 383× | (58.42%) |
| Mar 2026 | 920× | 68.87% |
| Dec 2025 | 545× | (30.81%) |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRTCY PureTech Health PLC Sponsored ADR compare | −9.1× |
| ARVN Arvinas, Inc. compare | −0.5× |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| CRMD CorMedix Inc compare | 0.7× |
| ASMB Assembly Biosciences, Inc. compare | 0.8× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 1.6× |
| PRTA Prothena Corporation plc compare | 2.6× |
| GYRE Gyre Therapeutics, Inc. compare | 3.5× |
| OCS Oculis Holding AG | 176× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)